TRIO-012: A multicenter, multinational, randomized, double-blind phase iii study of imc-1121b plus docetaxel versus placebo plus docetaxel in previously untreated patients with her2-negative, unresectable, locally recurrent or metastatic breast cancer

  1. MacKey, J.
  2. Gelmon, K.
  3. Martin, M.
  4. McCarthy, N.
  5. Pinter, T.
  6. Rupin, M.
  7. Youssoufian, H.
Revista:
Clinical Breast Cancer

ISSN: 1526-8209

Ano de publicación: 2009

Volume: 9

Número: 4

Páxinas: 258-261

Tipo: Artigo

DOI: 10.3816/CBC.2009.N.044 GOOGLE SCHOLAR

Obxectivos de Desenvolvemento Sustentable

Fonte de datos: Scopus